.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, individuals along with metastatic intestinal growths who received biomarker-matched therapies based on distributing growth DNA profiling presented a better medical perk than those receiving incomparable treatment.